ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,631.22
0.28%
US Tech 100
19,847.60
0.01%
다우존스 지수
40,211.72
0.53%
Bitcoin
63,155.51
-2.62%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) 뉴스

VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:VNDA
일자시간출처헤드라인심볼기업
2023/04/2807:00PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/04/2506:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/04/2506:16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/2902:26PR Newswire (US)Vanda Prevails in Jet Lag Litigation Against the FDANASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1805:50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1720:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1720:00PR Newswire (US)Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of DirectorsNASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/1322:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/03/0708:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/2208:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1506:41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1503:34Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1104:50Edgar (US Regulatory)Schedule 13g
(sc 13g)		NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/1001:59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0922:24Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0906:10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0906:01PR Newswire (US)Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
2023/02/0208:30PR Newswire (US)Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023NASDAQ:VNDAVanda Pharmaceuticals Inc
2023/01/0623:00PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/2320:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/1921:00PR Newswire (US)Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical StudyNASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/1704:54PR Newswire (US)Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launchNASDAQ:VNDAVanda Pharmaceuticals Inc
2022/12/1420:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VNDAVanda Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:VNDA

최근 히스토리

FX
USDGBP
US Dollar vs Sterling
NYSE
DIS
Walt Disney
CCOM
US500
US 500
AMEX
XLE
Energy Select Sector SPDR
AMEX
XLF
Financial Select Sector
NYSE
AXP
American Express
NASDAQ
TSLA
Tesla
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
NVDA
NVIDIA
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
NYSE
MRK
Merck
SPI
SP500
S&P 500
FX
USDEUR
US Dollar vs Euro
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유